|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-9-1
|
|
pubmed:abstractText |
We previously identified the small molecule harmine as a regulator of peroxisome proliferator activated-receptor gamma (PPARgamma) and adipocyte differentiation. In an effort to identify signaling pathways mediating harmine's effects, we performed transcriptional profiling of 3T3-F442A preadipocytes. Inhibitor of DNA biding 2 (Id2) was identified as a gene rapidly induced by harmine but not by PPARgamma agonists. Id2 is also induced in 3T3-L1 preadipocytes treated with dexamethasone, 3-isobutyl-1-methylxanthine, and insulin, suggesting that Id2 regulation is a common feature of the adipogenic program. Stable overexpression of Id2 in preadipocytes promotes expression of PPARgamma and enhances morphological differentiation and lipid accumulation. Conversely, small interfering RNA-mediated knockdown of Id2 antagonizes adipocyte differentiation. Mice lacking Id2 expression display reduced adiposity, and embryonic fibroblasts derived from these mice exhibit reduced PPARgamma expression and a diminished capacity for adipocyte differentiation. Finally, Id2 expression is elevated in adipose tissues of obese mice and humans. These results outline a role for Id2 in the modulation of PPARgamma expression and adipogenesis and underscore the utility of adipogenic small molecules as tools to dissect adipocyte biology.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-10022839,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-10067894,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-10585876,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-10622252,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-10681562,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-10837022,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-10937998,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-11021798,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-12110166,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-12426306,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-12524424,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-12861022,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-12888293,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-15664998,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-16054042,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-16054051,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-16059715,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-16239924,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-17086188,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-17351296,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-17488638,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-17604724,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-7557387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-7926730,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-8001151,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-8654925,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-8946919,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18562627-9405372
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0888-8809
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2038-48
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18562627-3T3 Cells,
pubmed-meshheading:18562627-3T3-L1 Cells,
pubmed-meshheading:18562627-Adipocytes,
pubmed-meshheading:18562627-Adipogenesis,
pubmed-meshheading:18562627-Adiposity,
pubmed-meshheading:18562627-Animals,
pubmed-meshheading:18562627-Cell Differentiation,
pubmed-meshheading:18562627-Gene Expression,
pubmed-meshheading:18562627-Gene Expression Profiling,
pubmed-meshheading:18562627-Harmine,
pubmed-meshheading:18562627-Humans,
pubmed-meshheading:18562627-Inhibitor of Differentiation Protein 2,
pubmed-meshheading:18562627-Mice,
pubmed-meshheading:18562627-Mice, Inbred C57BL,
pubmed-meshheading:18562627-Mice, Obese,
pubmed-meshheading:18562627-PPAR gamma,
pubmed-meshheading:18562627-RNA Interference,
pubmed-meshheading:18562627-Signal Transduction,
pubmed-meshheading:18562627-Wnt Proteins
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Inhibitor of DNA binding 2 is a small molecule-inducible modulator of peroxisome proliferator-activated receptor-gamma expression and adipocyte differentiation.
|
|
pubmed:affiliation |
Howard Hughes Medical Institute, University of California, Los Angeles, California 90095, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
